论文部分内容阅读
目的：探讨抑癌基困MTS1／p16在人卵巢浆液性囊腺癌发生发展中的作用。方法：应用免疫组化检测10例正常卵巢组织，20例浆液性囊腺瘤，20例交界性策液性囊腺瘤，65例浆液性囊腺癌及有癌转移的阳性盆腔淋巴结中p16基因蛋白表达，用PCR－SSCP分析10例浆液性囊腺癌中有无p16基因第1、2外显子的突变。结果：正常卵巢、浆液性囊腺瘤、交界性浆液性囊腺瘤、浆液性囊腺癌及有癌转移的盆腔淋巴结中，p16基因蛋白表达阳性率分别为60％、55％、55％、12．3％、0％；10例浆液性囊腺癌均未发现p16基因第1、2外显子的突变。结论：p16基因功能失活可能与卵巢癌发生、发展相关，p16基因表达的检测可能成为判断浆液性卵巢肿瘤恶性度及预后的指标；浆液性卵巢癌p16基因突变率较低，可进一步扩大检测范围并作进一步研究。
Objective: To investigate the role of tumor suppressor MTS1 / p16 in the development of human ovarian serous cystadenocarcinoma. Methods: Immunohistochemistry was used to detect the expression of p16 gene in 10 cases of normal ovarian tissue, 20 cases of serous cystadenoma, 20 cases of borderline serous cystadenoma, 65 cases of serous cystadenocarcinoma and carcinoma metastasis Protein expression was detected by PCR-SSCP in 10 cases of serous cystadenocarcinoma of p16 gene exon 1 and 2 mutations. Results: The positive rate of p16 gene protein in normal ovary, serous cystadenoma, borderline serous cystadenoma, serous cystadenocarcinoma and pelvic lymph nodes with metastasis was 60%, 55% and 55%, respectively. 12.3%, 0%; 10 cases of serous cystadenocarcinoma did not find p16 gene exon 1 and 2 mutations. Conclusion: The inactivation of p16 gene may be related to the occurrence and development of ovarian cancer. The detection of p16 gene expression may be an indicator to evaluate the malignancy and prognosis of serous ovarian tumors. The mutation rate of p16 gene in serous ovarian cancer is low, which may further expand the detection Scope and for further study.